Jobs
-
A consortium called NOFLU has received €13 million from the European Health and Digital Executive Agency (HaDEA) under the EU4Health program to support development of an intranasal vaccine against influenza. The NOFLU consortium consists of… Read more . . .
-
According to SoftOx Defense Solutions, the Irish Health Products Regulatory Authority has approved a clinical trial application for the company’s SIS-02 Phase 1 study of SIS hypochlorous acid inhalation solution in healthy volunteers. SoftOx recently… Read more . . .
-
According to Gossamer Bio, the Phase 3 PROSERA trial of its seralutinib dry powder inhaler in patients with pulmonary arterial hypertension missed its primary endpoint of change in 6-minute walk distance from baseline. The company… Read more . . .
-
Iconovo announced that it has signed a letter of intent with CDMO Lonza related to development of spray dried formulation of inhaled biologics. The companies announced in January 2025 that Lonza would develop spray dried… Read more . . .
-
According to Savara, the FDA has accepted the company’s BLA for Molbreevi mogramostim inhalation solution for the treatment of autoimmune pulmonary alveolar proteinosis. In March 2025, Savara announced that it had completed a rolling BLA submission… Read more . . .
-
Cyrano Therapeutics has announced that the Phase 2 FLAVOR trial of CYR-064 intranasal theophylline soft-mist spray for the treatment of hyposmia (loss of smell) following viral infection did not demonstrate any safety or tolerability concerns,… Read more . . .
-
UK-based Essential Pharma announced that it has acquired the rights to market Bayer’s Ventavis iloprost trometamol inhalation solution for the treatment of primary pulmonary hypertension in all markets except for the US and Russia. Essential… Read more . . .
-
Experic, which offers a range of development and manufacturing services for DPIs, has announced the appointment of former Catalent Drug Delivery Solutions General Manager Matthew Mollan as Chief Executive Officer. According to the company, previous… Read more . . .
-
Iliad Biotechnologies announced that it has raised $115 million in a Series B financing to support continued development of the company’s BPZE1 intranasal vaccine against pertussis (whooping cough). The company said that it intends to… Read more . . .
-
Qnovia announced that a Phase 1 trial of RespiRx inhaled nicotine, which is delivered via a handheld nebulizer, demonstrated that the nebulized formulation produced a Tmax comparable to cigarettes with lower plasma exposure. Qnovia had… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland